{
    "brief_title": "Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)",
    "phase": "Phase 3",
    "drugs": "['AZD9833', 'AZD9833 Placebo', 'Anastrozole', 'Anastrozole placebo', 'Letrozole', 'Letrozole placebo', 'Palbociclib', 'Abemaciclib', 'Luteinizing hormone-releasing hormone (LHRH) agonist']",
    "drugs_list": [
        "AZD9833",
        "AZD9833 Placebo",
        "Anastrozole",
        "Anastrozole placebo",
        "Letrozole",
        "Letrozole placebo",
        "Palbociclib",
        "Abemaciclib",
        "Luteinizing hormone-releasing hormone (LHRH) agonist"
    ],
    "diseases": "['ER-Positive HER2-Negative Breast Cancer']",
    "diseases_list": [
        "ER-Positive HER2-Negative Breast Cancer"
    ],
    "enrollment": "300.0",
    "inclusion_criteria": "inclusion criteria: \n\n INFORMATION FOR TRIAL PARTICIPANTS - Participants can join the trial if they: \n\n Have advanced breast cancer that is not able to be treated with surgery or radiation; \n\n Have an ESR1 mutation in their cancer; \n\n Have breast cancer that is HR-positive and HER2-negative; \n\n Are currently being treated with a CDK4/6 inhibitor and an AI and have been taking these drugs for at least 6 months; \n\n Have not had their cancer get worse after taking an AI and CDK4/6 inhibitor; \n\n Are able to do their daily activities; \n\n Are at least 18. \n\n Full list of inclusion criteria: \n\n Proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent; \n\n Documentation of histologically confirmed diagnosis of estrogen receptor positive (ER+) /HER2- breast cancer based on local laboratory results; \n\n Currently on AI (letrozole or anastrozole) + CDK4/6 inhibitor (palbociclib or abemaciclib) \u00b1 LHRH as the initial endocrine based treatment for advanced disease; \n\n Eastern Cooperative Oncology Group performance status of 0 or 1; \n\n ESR1m detected by central testing of ctDNA; \n\n Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures; \n\n Adequate organ and marrow function. \n\n ",
    "exclusion_criteria": ": \n\n INFORMATION FOR TRIAL PARTICIPANTS - Participants cannot join the trial if they: \n\n Had certain types of tumors in the past that may come back; \n\n Are currently taking any other treatments for their cancer or other conditions including hormone replacements, medications, or supplements that could interfere with the trial treatment; \n\n Have or have had any major health problem, infection, or recent surgery that could make it difficult or dangerous to participate in this trial. \n\n Full list of ",
    "brief_summary": "The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib or abemaciclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.",
    "NCT_ID": "NCT04964934"
}